Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (2209)	7/15/1999 10:32:00 PM
From: DanZ	Read Replies (2) \| Respond to of 10293

<Since when is it necessary to conduct "clinical trials" for homeopathic quack medications?> First, your characterization of Zicam as a "homeopathic quack medication" is false. Aside from that, this question has been answered here over the past few days, and if you bothered to read any the messages, you wouldn't have wasted space on SI's server asking it again. Here are some reasons: 1. The FDA requires a company to conduct two clinical studies on products before they can claim that a product is "clinically proven" to do anything on the label or in their advertising. This is the primary reason that GelTech is conducting a second study on the efficacy of Zicam on reducing the duration of common cold symptoms. 2. GelTech/GumTech wishes to submit Zicam to a medical journal for review and possible publication. They can't do this without appropriate clinical data. As you should know by now, the first study on Zicam has already been submitted to the New England Journal of Medicine, what many consider to be the most prestigious medical journal in the world. 3. The clinical studies, if conducted according to accepted principles, should garner support of those in the medical community that are understandably skeptical of Zicam at this time. If published in the NEJM, many doctors will recommend Zicam to their patients as an inexpensive and effective remedy against the common cold. This will sell product, and that is GumTech's ultimate goal. 4. GumTech and GelTech are small and have limited financial resources. This has been discussed here and I don't disagree with it. The company is trying to use their cash in the most intelligent manner possible, and decided that if their clinical study was accepted by a major medical journal, they would get free PR as a result. In other words, they will get more bang for the buck by spending money on a clinical study than advertising because they are confident that Zicam works and they are confident that a major medical journal such as the New England Journal of Medicine will publish it. This is a very smart business decision, and is contrary to the BS that one reads on this thread from those who want to paint a negative picture of GumTech's management. <Why do I get the feeling that the company will tell us the results of these "trials" will be a smashing success?> It really makes no difference what the company says about the results of the clinical studies. No reputable medical journal would publish the results unless they agree with them. Why do I get the feeling that you will say somebody pulled something over on the NEJM if they publish the study? <GUMM is fraudulently promoting a quack remedy to artificially inflate its stock and should continue to be shorted on any upticks.> IMO, you are manufacturing tainted stories that border on fraud and libel in a lame attempt to garner support in the market for your losing short position in GUMM. Getting a little nervous about your short position?

To: Bill Wexler who wrote (2209)	7/15/1999 10:41:00 PM
From: Starfish*	Respond to of 10293

Mr. Wexlar, Since the topic tonight is medical scams CYBX expected to lose -.72 this year and make .14 next year??? biz.yahoo.com How can they do it? 87K in cash, 4.5 million liabilities biz.yahoo.com 4th Q increased only because CEO stuffed the channels, and quit. biz.yahoo.com Not much insider selling. I thinks it could happen with a little pump. biz.yahoo.com I haven't found the reporting date yet but I will be looking for the opportunity for a downhill run again. Do you still follow this one?